- Home
- BBD vs WAT Comparison
BBD vs WAT Comparison
Compare BBD & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBD
- WAT
- Stock Information
- Founded
- BBD 1943
- WAT 1958
- Country
- BBD Brazil
- WAT United States
- Employees
- BBD N/A
- WAT N/A
- Industry
- BBD Major Banks
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- BBD Finance
- WAT Industrials
- Exchange
- BBD Nasdaq
- WAT Nasdaq
- Market Cap
- BBD 30.6B
- WAT 17.8B
- IPO Year
- BBD N/A
- WAT 1995
- Fundamental
- Price
- BBD $3.13
- WAT $295.50
- Analyst Decision
- BBD Strong Buy
- WAT Hold
- Analyst Count
- BBD 4
- WAT 14
- Target Price
- BBD $2.55
- WAT $374.07
- AVG Volume (30 Days)
- BBD 32.9M
- WAT 586.5K
- Earning Date
- BBD 10-30-2025
- WAT 10-31-2025
- Dividend Yield
- BBD 4.96%
- WAT N/A
- EPS Growth
- BBD 58.81
- WAT 10.77
- EPS
- BBD 0.36
- WAT 11.09
- Revenue
- BBD $16,114,445,927.00
- WAT $3,046,056,000.00
- Revenue This Year
- BBD $72.65
- WAT $7.19
- Revenue Next Year
- BBD $8.90
- WAT $6.40
- P/E Ratio
- BBD $8.13
- WAT $26.65
- Revenue Growth
- BBD 27.09
- WAT 5.89
- 52 Week Low
- BBD $1.84
- WAT $275.05
- 52 Week High
- BBD $3.24
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- BBD 59.17
- WAT 47.98
- Support Level
- BBD $3.11
- WAT $288.90
- Resistance Level
- BBD $3.20
- WAT $303.24
- Average True Range (ATR)
- BBD 0.07
- WAT 8.76
- MACD
- BBD 0.01
- WAT 0.63
- Stochastic Oscillator
- BBD 60.34
- WAT 37.96
About BBD Banco Bradesco Sa
Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation—a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.